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The design of 3D complex structures enables new correlation studies between the engineering 
parameters and the biological activity. Moreover, additive manufacturing technology could 
revolutionise the personalised medical pre-operative management due to its possibility to interplay 
with computer tomography. Here we present a method based on rapid freeze prototyping (RFP) 3D 
printer, reconstruction cutting, nano dry formulation, fast freeze gelation, disinfection and partial 
processes for the 5D digital models functionalisation. We elaborated the high-resolution computer 
tomography scan derived from a complex human peripheral artery and we reconstructed the 3D model 
of the vessel in order to obtain and verify the additive manufacturing processes. Then, based on the 
drug-eluting balloon selected for the percutaneous intervention, we reconstructed the biocompatible 
eluting-freeform coating containing 40 nm fluorescent nanoparticles (NPs) by means of RFP printer 
and we tested the in-vivo feasibility. We introduced the NPs-loaded 5D device in a rat’s vena cava. 
The coating dissolved in a few minutes releasing NPs which were rapidly absorbed in vascular smooth 
muscle cell (VSMC) and human umbilical vein endothelial cell (HUVEC) in-vitro. We developed 5D high-
resolution self-dissolving devices incorporating NPs with the perspective to apply this method to the 
personalised medicine.
Chronic lower extremity peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis, and one 
of the main causes in loss of walking ability. Two treatments for lower extremity PAD are currently available: sur-
gical (primarily bypass surgery) and endovascular treatment (EVT) mainly through balloon angioplasty. In fact, 
due to its clear advantages at least in the short-term, EVT represents – at present – the most common treatment 
for PAD1. Drug-Coated Balloons are made up of a semi-compliant or non-compliant balloon catheter covered 
with an anti-proliferative agent (typically paclitaxel), and an excipient (e.g. urea) to facilitate drug transfer into 
the vessel wall after balloon inflation2. The BASIL (Bypass Versus Angioplasty for Severe Ischemia of the Leg) trial 
is the only multicentre, randomised and controlled trial (RCT) which compared these two treatments3. One of 
the major limitations of this RCT is that current endovascular technologies have not been included4. Important 
advances developed in endovascular technologies address a great variety of anatomic challenges, while current 
and future efforts are directed towards improving long-term patency rates.
The 3D printing techniques demonstrate the high potentiality of interactive processes applied to medicine 
and associated toxicity/vitality studies5,6. Materials selected for bio-printed scaffolds are predominantly based on 
both naturally derived polymers (including gelatine, collagen, alginate, chitosan and hyaluronic acid) or synthetic 
molecules (polyethylene glycol)7–9, allowing precise control10 of chemical and physical properties11.
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The 5D printing merges data used to create 3D models with data regarding physiological activity for per-
sonalised therapy12. In the present work, we describe how the 5D additive manufacturing method is applied to 
create personalised models of patients’ pathology. In detail, we used available 3D printing technology to identify 
the operative processes13 and the related parameters able to reach the best fit between the digital model and 
final object. Thus, we selected bio-inks and new composite materials to satisfy the final functional application 
(4D). Finally, we customised macro/micro morphologies and biological properties (5D), merging the engineered 
devices with the shape obtained from the patient. The subsequently drug integration and in vivo analysis enable 
the implementation of the personalised medicine.
Results
The 5D printing technique12 incorporates data regarding 3D printing technologies with local control composition 
of the biomimetic materials (+1D), and particles distributions14 able to reproduce the real organ response dur-
ing the physiology studies (+1D). We reconstructed the 3D model from patient’s CT obtaining the nano-laden 
aerogel for the fast release of nanoparticles (NPs). The bioprinted devices were used to realise a biomimetic 
bio-composite material (4D) for the in vitro and in vivo tests. Finally, customising the 4D model using particles 
that directly interact with the organ physiology we obtained a 5D bioprinted device.
The design of a standardised approach, to develop 5D printed devices, required 3 phases (Table 1): 
pre-printing, printing and post-printing15. Each phase requires the analysis and the validation of the following 
modelling steps: i) requirement, ii) model orientation, iii) trajectory generation, iv) printing process analysis and 
v) digital model adherence16.
Using a Peltier-based system (Supplementary Fig. S1a), we developed soft scaffolds (Supplementary Fig. S1b) 
with complex shape (Supplementary Fig. S1c). The implemented cooled bed (Supplementary Fig. S1d) demon-
strated the ability to reach −30 °C in 19.6 ± 0.9 s (31.2 ± 0.1 °C in 120 s) and return to room temperature 
(ΔT = 57 °C) in 25.4 ± 0.7 s.
The selected mechanical micro-extrusion technology17,18, with volumetric planning, did not require any pro-
cess change in the use of different materials or bio-ink viscosities (Supplementary Fig. S2a). This is known to 
be impossible by pneumatic control extrusion without real-time pressure adaptation (Supplementary Fig. S2b–
d). The fresh filament diameter, measured after 3D printing, demonstrated that 11% of alginate (Fig. 1a, green 
columns) was the optimal biomaterial concentration to obtain dimensions very close to the designed value 
(Φ = 292 µm, inner diameter of 26G syringe needle). In fact, using 7% and 9% alginate solutions in the fabrication 
of a scaffold with 400 µm of macro-porosity it is very challenging to maintain the bridge for the required freezing 
time. Thus, it is required a low environmental temperature to subtract the thermal energy in less time or in the 
case instead, to maintain the same speed, we have to enlarge the filament diameter with the final aim to better 
distribute filament weight. The minimum deposition speeds for the different percentages of biomaterial, assuring 
regular shape distribution, were 6 mm/s for 11% of alginate (Fig. 1b), 10 mm/s for 9% of alginate (Fig. 1c) and 
14 mm/s for 7% of alginate. Finally, with the minimum speed (6 mm/s) and maximum concentration (11% of 
alginate) that we used for 3D bioprinting, we also performed a validation test of both corners and drop (Fig. 1e,f), 
demonstrating the high resolution of the applied technology.
We developed the fast release therapy through the bioprinting fixation (Fig. 2a) followed by freeze gelation, 
using ethanol19 (Fig. 2b), enabling the fabrication of 5D nano-laden hydrogel (Fig. 2c). We printed eight scaffolds 
with and without 40 nm fluorescent NPs (Fig. 2d), the scaffold dissolved in Dulbecco’s Modified Eagle’s Medium 
(DMEM), in 198.3 ± 1.6 s and 207.3 ± 2 s respectively, unlike the typical CaCl2 gelation scaffold (Fig. 2e) that 
displays the same structure after 24 h. Accordingly to scanning electron microscopy (SEM) images, the scaffolds 
METHOD PARAMETERS OPERATIVE PROCESSES PRINTING PHASES
ORGAN PRINTING 
PHASES
PARAMETERS IDENTIFICATION Region of interest Imaging acquisition (CT, MRI, PET) Images processing sectioning and cell isolation
PRE-PRINTING
MATERIALS SELECTION Process Technological sizing based on the material properties Formulation
TECHNOLOGY ASSESSMENT Geometrical CATE (computer aided tissue engineering) processing Blueprint
PRE-PROCESSING RECONSTRUCTION Printing 3D imaging digitization and printing simulation
3DRC (3D reconstruction cutting) and 
digital bio-library related to the model




Definition of dynamic and active 
properties NDF (nano dry formulation)
5D CUSTOMISATION Pathology and physiology Health device development
3DPP (3D partial processes) and digital 
bio-library functional customisation
THERAPY Predictive Biological tests Biomonitoring
POST-PRINTING
SYNTHETIC ORGAN 
TRANSPLANTATION Health guideline Clinical analysis Treatment and validation
BIO-BASED SMART BIOPRINTING Adaptive Smart processing Human mimicry and autonomous regeneration
Table 1. Organ printing schema and FANNAM method (from pre-processing reconstruction to 5D 
customisation) describing the used methods, the parameters, the operative processes for each organ printing 
phases.
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printed with alginate showed an extremely porous and fibrillary microstructure. The high surface area led to 
a greater interaction with biological tissues (Fig. 2f). On the contrary, structures gelled with ethanol (Fig. 2g) 
showed a more compact and less porous microstructure, characterised by a higher speed of resorption, release of 
drugs and reduced surface volume ratio20.
Preliminary in-vitro analysis on vascular smooth muscle cells (VSMCs) (Fig. 3), demonstrated that cell viabil-
ity in both the gelation processes and dissolution (direct and indirect methods) did not change, when compared 
to control.
Furthermore, we observed NPs internalisation into cells, following dissolution of the structures (Fig. 4a) in 
VSMC thickness via stimulation-emission depletion (STED) (Fig. 4b–d) confocal microscopy. To confirm the fea-
sibility21 of these methods in-vivo, we inserted the same NPs-laden structures in rat’s vena cava and we observed, 
after fast dissolution, NPs internalisation into both the interstitial tissue and the vascular cells (Fig. 4e–g).
Finally, cellular viability and metabolism were evaluated in human umbilical vein endothelial cell (HUVEC) 
line in order to understand if each step of our printing method can alter cell surviving. It was evident that the 
percentage of alginate (11%), that we used for our biological application, did not influence cellular viability and 
metabolism in both direct (Fig. 5a,c,e) and indirect (Fig. 5b,d,f) dissolution. Moreover, gelation and NPs admin-
istration did not alter the HUVECs viability and metabolism (Fig. 5a–f). To confirm if NPs interact with our cell 
line, we also performed cytofluorimetric analysis showing that HUVEC are capable to bind and/or internalise 
NPs with little changes after 24 h of administration (Fig. 5g).
Figure 1. Scaffold macro-morphological characterisation and resolution assessment. (a) Scaffold filament 
diameter at different speed and alginate concentration with volume integration: 11% (green), 9% (purple), 7% 
(orange); (b) Printed scaffolds with 11% of alginate concentration under (left panel) and over (right panel) the 
minimum speed (6 mm/s). (c) same as (b) for printed scaffolds with 9% of alginate concentration and minimum 
speed of 10 mm/s. (d) same as (b) for printed scaffolds with 7% of alginate concentration and minimum speed 
of 14 mm/s. (e) Example of validation tests of printed corners at 60°, 45° and 30°:.STL file (left panel); printed 
trajectory (right panel). (f) Example of validation tests of printed drops:.STL file (left panel); printed trajectory 
(right panel). Wilcoxon sign rank test was performed and statistical significance was set at p < 0.05. Data are 
represented as median ± discrepancy.
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The positive results obtained from in-vitro and in-vivo studies allowed us to move from functionalisation 
method (4D) to customisation method (5D). Then, we printed a model of a complex femoral artery bifurcation 
(Supplementary Fig. S3) directly from a patient’s computed tomography (CT)-scan with the aim to reconstruct, 
by 3D bioprinting, the portion of interest (Supplementary Fig. S4) with sodium alginate-based material. We 
functionalised the bio-ink with interface and reinforcement (composite biomaterial) (Fig. 6a), developing the 
required functionalisation for the proposed therapy or application. The obtained composite biomaterial was used 
to manufacture a new type of fibre, its interface and matrix, for bio-composite material (Fig. 6b) customisation 
with different functional matrix (cellular adhesion, gradual release, etc.) (Fig. 6c). Thus, merging this material 
with the correct technology parameterisation, we printed and perfused a complex vessel system (Fig. 6d–f).
The fibre (Fig. 6g) allows the scaffold engineering (performance mimicry, vascularisation for the cells via-
bility); the surface micro-morphology modification (Fig. 6h) enables the different types of applications (cells 
adherence, active or passive stimuli response), and with different types of coating and matrix we can customise 
the 4D bio-composite materials22 (Fig. 6i). Moreover, to realise the nano-laden scaffold we can print a composite 
biomaterial or rehydrating an aerogel scaffold. After that, implementing the adhesive coating and the matrix we 
can customise the biological device (Fig. 6j) to achieve the desired physiological properties (Fig. 6k).
Figure 2. 3D Fast Freeze Gelation, dissolution time and micro-morphology. (a) Freeze fixation; (b) Freeze 
gelation; (c) Scaffold detail displaying fluorescence spots. (d) Dissolution time of alginate ethanol gelled scaffold 
in DMEM, without (grey) or with (white) nanoparticles. (e) Alginate based scaffold (gelled with CaCl2) after 
24 h conservation in DMEM. (f) Alginate SEM images of 3D printing scaffold gelled with CaCl2 and with 
(g) ethanol at different magnifications. Unpaired t-test was performed and statistical significance was set at 
p < 0.05. ** vs without nanoparticles. Data are represented as mean ± SEM.
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Finally, we obtained a 5D bioprinted device12 performing a customised coating balloon for the controlled 
release tests of new elements (Fig. 7a–d). The resulted fabrication process sets the basis for the post-printing 
phases and “6D” smart material device (i.e. autonomous regeneration), starting from the organ reconstruction 
for therapy customisation and the related training for the continuous improvement (Fig. 7e–g), to the controlled 
release systems for the functionalisation of long-term vascularised scaffold (capillary systems) (Fig. 7h).
Discussion
The realisation of organs and living synthetic tissues requires biomimetic bio-papers (bio-scaffolds) for cell seed-
ing, vascular systems for long-term perfusion18 and a precise cell deposition process with the related scaffold 
customisation for 5D technique implementation and biomimicry screening. For example, the macro-structure 
selection must permit the synthetic organ function biomimicry (i.e. vessel contraction) while the surface mor-
phology modification should guarantee the cells adherence and the related viability.
Using the Formulation and Analysis for Nanoparticle Additive Manufacturing (FANNAM) method15,23 
(Table 1) applied to the reconstruction of PAD, it is possible to carry out pre-surgical training23,24 and 5D 
short-term medical device, identifying the correlation and the related scheduling between methods steps, param-
eters, operative processes and the printing phases related to organ printing. The production of 5D printed soft 
tissues (cf. Table 1) requires: i) evaluation of the parameters that resume the interaction between the 3D printed 
object and the selected biological tissue, ii) functionalisation to apply operative processes in health application 
and iii) validation of the printing phases with 3D partial processes and customisation of digital bio-library. The 
3D pre-printing process requires three major steps: image acquisition and curation, slicing and analysis, computer 
aided tissue engineering (CATE) processing and printing. Image acquisition is usually obtained with CT, due 
to its rapid sampling. Volumetric data are rendered in digital imaging and communication, in medicine format 
(DICOM), that cannot be 3D printed25. Thus, image data require conversion in stereolithography (STL) format, 
using a specialised software26, then the g-code generated by computer aided manufacturing (CAM) controls the 
motors. The selected material and its customisation address the selection of technology and the correct printing 
parameters for its manipulation. The process assuring the total quality improvement starts by identifying the type 
Figure 3. VSMC Viability. (a) Calcein AM-loaded VSMC after scaffold solubilisation with (b) direct or (c) 
indirect method, gelled with EtOH (left panels) or CaCl2 (right panels). VSMC viability (Live/Dead assay) after 
dissolving the scaffold, gelled with EtOH or CaCl2, with (d) direct or (e) indirect method. Unpaired t-test was 
performed and statistical significance was set at p < 0.05. Data are represented as mean ± SEM.
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of object27 and the quality evaluation of the results for the adopted production technology and concerns: material 
properties, geometric parameters, micro-porosity, the degradation of the gelled object, as well as the vitality of the 
cells and/or the toxicity of the material. Rapid freeze prototyping technology enables the possibility to develop 
high defined scaffolds and the proposed method improves the current state of the art28,29. In fact, we reached the 
same resolution of existing technology18,30 but without the use of toxic photo-activators, indispensable for the 
stereolithographic apparatus (SLA). Moreover, compared to both selective laser sintering and SLA we do not have 
material waste and we can utilise cell-laden bio-ink, not possible with fused deposition modelling that reaches 
temperatures over 37 °C.
High resolution was achieved by identifying 46 geometrical parameters18 for the scaffold analysis, developing 
a continuous improvement operative process to better understand and validate the deviation trend and utilising 
the inner diameter value as “filament parameter”. Problems regarding the height of the layer were removed and 
variance using the geometrical parameters was reduced28,31 as well as the incomplete lap, the over accumulation 
and the redundant lap32. In this context, viscosity plays a pivotal role in the deposition of filament without support 
(bridge). In fact, it is well known that alginate dissolved in bovine serum affects the rheological properties of poly-
mer mixture solution33 and the viscosity is directly related to the alginate concentration and is inversely related to 
temperature34. Indeed, the development of shape with high viscosity material becomes very easy in printing, how-
ever the energy that has to be subtracted from the scaffold and/or the time for the freezing phase has to be added.
In order to identify the region of interest, defined by the material, we generated a digital model and the related 
digital bio-library able to control the manufacturing phases. This library requires a lot of validation since we can 
apply the same file for its development with the higher number of hard and soft materials.
For the reasons exposed above it is mandatory that the identification of macro-morphology resolution is 
merged with the printing parameters lower limits. The FANNAM method includes four processes: 3D recon-
struction cutting (3DRC), 3D fast freeze gelation (3DFFG), nano dry formulation (NDF) and 3D partial pro-
cesses (3DPP), designing new digital elaboration steps to define the best correlation between different materials 
and technology. The final aim is the definition of an excellent printing configuration17 and an alginate-based 
material formulation with embedded NPs, simultaneously disinfecting the material. With 3DRC we are able 
to reconstruct the missing biological components, defining the best fit between 3D model and final trajectory 
Figure 4. Scaffold-derived nanoparticles internalization. (a) Aerogel scaffold and filament after more than 12 
months of storage in the petri dish. (b) Frontal view obtained by STED confocal microscopy of wheat germ 
agglutinin (WGA) stained vascular smooth muscle cells (VSMC, red) that included nanoparticles (green). (c) 
Orthogonal view showing the same nanoparticles into the cultured cells. (d) Render image obtained by the 
white square in “b” showing nanoparticle internalization from the VMSC membrane. Nanoparticle diameter: 
40 nm. (e) Two-photon microscopy imaging of a WGA-stained rat vein. (f) Same as (e) with a vein exposed to 
the scaffold containing nanoparticles, showing the internalization of the nanoparticles in the VSMC cells. (g) 
same as (f) with high-scan resolution.
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Figure 5. In-vitro viability and metabolism evaluation in HUVEC line. (a) cell number evaluation at 2 h, 
24 h and 48 h after scaffold direct dissolution in: (i) control cell (first column); (ii) cells after 11% of alginate 
administration (second column); (iii) cell after 11% of alginate administration and ethanol crosslinking (third 
column); (iv) cell after 11% of alginate administration, ethanol crosslinking and NPs administration (forth 
column); (v) cell after NPs administration (fifth column). (b) same as (a) for scaffold indirect dissolution. (c) 
cell viability evaluation at 2 h, 24 h and 48 h after scaffold direct dissolution in: i) control cell (first column); (ii) 
cells after 11% of alginate administration (second column); iii) cell after 11% of alginate administration and 
ethanol crosslinking (third column); (iv) cell after 11% of alginate administration, ethanol crosslinking and 
NPs administration (forth column); (v) cell after NPs administration (fifth column). (d) same as (c) for scaffold 
indirect dissolution. (e) ATP evaluation at 2 h, 24 h and 48 h after scaffold direct dissolution in: (i) control cell 
(first column); (ii) cells after 11% of alginate administration (second column); iii) cell after 11% of alginate 
administration and ethanol crosslinking (third column); (iv) cell after 11% of alginate administration, ethanol 
crosslinking and NPs administration (forth column); (v) cell after NPs administration (fifth column). (f) same 
as (e) for scaffold indirect dissolution. White columns: control cells; grey columns: cells with 11% of alginate 
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related to printing materials. Alginate based materials with NPs, used for these experiments, were made with 
NDF, without NPs waste and aiming to ensure low variance in the evaluation of released nano-laden material. We 
implemented 3DFFG that permits the fast gelation, the release of alginate in a very short time (approx. 2–3 min-
utes) and simultaneous disinfection35, enabling the long-term preservation without any added treatment. In fact, 
once the adherent printed object is obtained with the digital model, the instantaneous gelation closed the loop for 
scaffold fabrication, fixing the freezed scaffold instantaneously.
The functional adherence of the object, the amount of material used and similarity with the digital model are 
assured via the 3DPP that includes all activities of configuration, calibration or modification carried out in the 
processes and stages of 3D model development, which competes for maximum quality performance. Partial pro-
cesses are therefore mandatory in the development of objects through rapid prototyping and viscous materials. 
For example, changing the development speed on a machine with a subtractive technology, the surface roughness 
alteration does not modify the mechanical characteristics, but using the additive manufacturing technology to 
realise cake decorations, its morphology changes, with the functional aim of the object (aesthetics). Thus, the 
assessment of the parameters is directly related with the functionality of the 5D object and in the case of the 
soft tissue development we have to take in consideration drops accidentally falling down or the creation of vas-
cular channel to bring, where required, the gelation fluid for the morphology long-term fixation and dedicated 
tests33,34,36–41 are required to better explore any manufactured object and each possible customisation.
Finally, post-print and analyses increase the quality and the biological potentials of digitalised pathological 
models and the evaluation of the printed 5D model adherence assuring a continuous improvement system with 
the use of a custom CATE for the smart and fast storing of all processed data in new digital library pathology.
Thanks to the high scaffold customisation potential (NP or functionalised matrix for a gradual drug release), 
we can design and bioprint 5D personalised medical devices. In detail, modifying the composite biomaterial42–45 
and the manufacturing methods, the interaction45,46 of the transplanted structures with the biological substrate 
can be varied accordingly to experimental needs. When it is possible to graft biocompatible objects (prosthesis, 
STENT, etc.) and activate the functionalised material for restoring physiological activity with, for example, exter-
nal stimuli (electrical, magnetic, photonic, etc.) or chemical agents, the 5D printing becomes “active”14,47,48. Thus, 
thanks to the analyses and the digitalisation of the diseases over the time, it is possible to validate and determine 
key directives in order to develop the region of interest for the scaffolds for future in-vivo tests and Food and Drug 
Administration/European Medicine Agency (FDA/EMA) draft about nano-functionalised 5D printed devices.
This method can be applied to different types of material and gelation, and we utilised alginate, gelling the scaf-
fold with EtOH and CaCl2. The two developed biomaterial scaffolds resulted in very different micro-morphology 
as well as functional application but both showed low impact on cell death. Dissolving the nano-laden scaffold in 
a solution with VSMC and subsequently into the rat vena cava, the developed devices demonstrated the ability 
to control gradual release, very similarly to STENT applications, the vehiculation of NPs and long-term storage 
potential. Reproducing the same tests on HUVECs, the results demonstrated the potential of human scaling of 
the proposed method. The high variability in biological application requires rigorous standards for analysis and 
we identified a good scheduling for the 5D processes and parameters digitalisation with the aim to support the 
synthetic organ development and the digital bio-library improvement. Our method showed that is possible to 
develop nano-laden 5D devices for training, pharmacological tests and in-vivo applications, improving the typical 
drug eluting balloon therapy merging patient morphology with the high resolution of rapid freeze prototyping 
technology.
Materials and Methods
3D bioprinter, thermal analysis and model design. The rapid freeze prototyping bioprinter (Bio-
4esti)18, placed under a biosafety cabinet (HeraSAFE Heraeus, Thermo Fisher scientific, Waltham, MA, USA) 
is equipped with two mechanical extruders24 for 5 ml syringes (BD Emerald, Franklin Lakes, NJ, USA) and a 
removable Peltier cold plate. The cold plate temperature was measured with a Flir A325 infrared camera (Flir 
Systems, Wilsonville, OR, USA). The analysis of the thermal behaviour was carried out using the application 
FLIR ResearchIR v.1.2 (Flir Systems, Wilsonville, OR, USA). With this software tool, it is possible to evaluate the 
minimum, the maximum and the average temperatures of a selected rectangle of an image, or a movie, taken by 
the camera. In our case, the rectangle was fitted on the cold plate.The scaffold was designed using SolidWorks2015 
(Solidsolution, London, UK) and sliced with Slic3r open source software.
Nano-functional scaffold development. In our experiment two different materials are used: alginate 
powder18 (W201502, Sigma-Aldrich, Steinheim am Albuch, Germany) that is a low-cost hydrosoluble biomate-
rial used for sweets fabrication or for molecular cuisine, and natural polylactic acid (PLA)11 (175N1, Velleman 
Inc., Legen Heirweg, Gavere, Belgium) without colour pigments (diameter 1.75 mm (1/16′), density 1.25 g/cm3 
(at 21.5 °C), printing temperature 190–225 °C, impact strength 5 kJ/m2) which recently demonstrated its use for 
clinical applications49.
scaffold; pink columns: cells with 11% of alginate scaffold gelled with EtOH; blue columns: cells with 11% of 
alginate scaffold gelled with EtOH containing NPs: yellow columns: cells with NPs. (g) Cytofluorimetric analysis 
of HUVEC control cell after 24 h (black trace), HUVECs and alginate after 24 h (red trace), HUVECs and 
alginate plus NPs after 2 h (green trace) and after 24 h (blue trace). Kruskal-Wallis (post hoc analyses: Dunn’s 
multiple comparison) was performed and statistical significance was set at p < 0.05. Data are represented as 
mean ± SEM.
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NDF. Immediately before the experiments, in order to minimise particle aggregation, all NPs (40 nm Fluorescent 
nanobeads, Thermofisher, Milano, Italy) were sonicated (Branson Ultrasonics, Danbury, CT, USA) for 30 mins at 
T = 37 °C and 3 µl (50 µg/ml) of NPs solution were added into sodium alginate powder. Subsequently, high glu-
cose DMEM w/o Phenol Red (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) was added to achieve a final 
alginate solution concentration of 7%, 9% and 11% wt/vol.
Figure 6. Bio-composite material vessel fabrication. (a) Composite biomaterial (bio-based, biocompatible and 
biodegradable): matrix (red, functions), interface (green, performance and stability) and reinforcement (yellow, 
fibre, nanoparticles, nano-tubes, etc.). (b) Bio-composite material (Nano-functionalised 4D bio-engineered 
scaffold): matrix (blue, functions), interface (green, performance and stability) and fibre (red, composite/
biocomposite scaffold reinforcement).(c) Bio-composite material vessel schema: nano-laden fibre (yellow 
points and red), interface (green), not functionalised matrix (blue) and functionalised matrix (white). (d) 
3D digital model of complex vessel. (e) Complex vessel section; (f) Nano-functionalised 4D Bio-engineered 
scaffold perfusion test. (g) Complex geometry aerogel scaffold (left panel) and related detail (right panel, 4x 
magnification). (h) Aerogel with functionalised surface micro-porosity (left panel) and related detail (right 
panel, 4x magnification). (i) Nano-laden bioengineered scaffold (left panel) and related detail (right panel, 4x 
magnification). (j) Dehydrated 5D bioprinted vascular device after more than 24 months of petri dish storage. 
(k) Bio-composite material customisation schema: nano-laden fibre (yellow points and red), interface (green), 
not functionalised matrix (blue), functionalised matrix for dedicated cells (yellow), adhesive coating (black) and 
customised matrix for physiology analyses (white point and violet).
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3DFFG. Scaffolds were printed onto aluminium plate with a temperature of about −30 °C (at room tempera-
ture), using a 26 G needle (BD Emerald, Franklin Lakes, NJ, USA) and covered by ethanol 95%, for the simulta-
neous gelation and disinfection50,51 phases. In detail, the nano-laden scaffolds for the in vitro and in vivo analyses 
were developed with alginate 11% at 6 mm/s of printing speed.
Micro-porosity characterisation. In order to obtain morphological information on the 3D printing scaf-
folds, SEM characterisations were performed using a field emission SEM (FESEM, Nova NanoSEM 450, FEI com-
pany, Hillsboro, OR, USA). Images were acquired in field-free lens mode using the Everhart-Thornley detector for 
the secondary electron imaging signal. The accelerating voltage of 10 kV, the spot size of 4.5 nm and the working 
distance of 6 mm were used in the acquisition of all images.
In-vitro VSMCs analysis and dissolution test. Cell culture. Mice VSMCs were kindly provided by Prof. 
Leonardo Elia (Istituto Clinico Humanitas Rozzano, Milano, Italy). VSMC was cultured in DMEM (high glucose) 
with 2 mM glutamine, 10% fetal bovine serum (FBS, Euroclone, Milano, Italy) and 1% penicillin/streptomycin 
(5,000 U/mL). Cells were cultured as recommended and maintained under standard cell culture conditions at 37 °C 
in a water-saturated atmosphere of 5% CO2 in air. We seeded 3×105 VSMCs in a 50 mm petri dish for direct and 
indirect measurement (n = 8). The direct measurement consists in adding after 24 hrs to the culture the alginate 
scaffold-enriched NPs (50 µg/ml) crosslinked with ethanol, as described previously. In regards to the indirect method, 
the same scaffold-enriched NPs were totally dissolved directly in the medium before being added to the culture.
Figure 7. The 5D customised scaffold. (a) 5D soft scaffold printing phase. (b) Composite biomaterial scaffold 
with green (upper panel) and red (lower panel) fluorescent nanoparticle. (c and d) Integration of soft and hard 
materials for gradual release tests, respectively. (e) Femoral bifurcation model for STENT training. (f) Surfaces 
detail of not printable.STL model with 3D digital reconstructed model. (g) 3D PLA printed model without 
pathology. (h) Capillary vascular bifurcation with 0.65 mm inner diameter and 1.7 mm outer diameter, model 
design (upper panel) and 3D printed object (lower panel).
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Viability assay. To evaluate cell viability, VSMCs were counted in a Bürker hemocytometer by trypan blue 
exclusion method and evaluated under a phase contrast microscope. The viability of cells was also confirmed 
using calcein AM staining (Thermo Fisher, Waltham, MA, USA). Specifically, after the treatment the media was 
replaced with a fresh one containing 5 µM Calcein AM. After 30 mins of incubation at 37 °C in 5% of CO2, cells 
were washed twice with phosphate buffered saline (PBS) before being imaged with an upright fluorescent micro-
scope (Leica Microsystem, Wetzlar, Germany) through a x20/0.7 or ×40/1.3 oil objective.
Scaffold dissolving methods. We performed two different dissolving methods: direct and indirect.
 1. Direct method: the scaffold was placed directly in the petri dish containing cells with 4 ml of culture 
medium.
 2. Indirect method: the scaffold was placed and dissolved in a 15 ml tube into 2 ml of culture medium; once 
the scaffold was dissolved, were added 2 ml more of culture medium and then this solution was added in 
the petri dish, where the cells were previously cultured.
Experimental animals. Two Sprague Dawley Rats have been used in these experiments accordingly to the 
local ethical guideline and the protocol was approved by the Italian Ministry of Health (Prot. N 989/2017-PR). All 
the procedures followed the directives of the European Law 63/2010 and the Italian law 26/2014 for the experi-
mental animal use. Briefly, we anesthetised animals as previously described52 and the vena cava was exposed after 
surgery. The upper part of the vena cava was ligated and the NPs-laden scaffold was inserted after a 1 cm distal 
to occlusion small incision. We left the scaffold for 2 minutes in the vena and then we rapidly removed this area, 
washed in PBS, longitudinally opened and fixed in 4% buffered formalin solution for 24–48 h till two-photon 
microscopy evaluation.
In-vitro and In-vivo microscope analysis. STED microscopy. The cells were fixed on a cover glass 
(thickness n°1.5) with 4% paraformaldehyde (PFA) for10 mins, for the STED microscopy, blocked, and perme-
abilised with 3% normal goat serum, 0.1% Triton X-100 in 1 x PBS for 1 hour as previously described53. Briefly, 
STED xyz images were acquired with a Leica SP8 STED3X confocal microscope system (Leica Microsystem, 
Wetzlar, Germany). Green NPs (Molecular Probes, Eugene, OR, USA) were excited with a 488 nm Argon Laser 
and emission was collected from 507 to 614 nm, while wheat germ agglutinin (WGA, Thermo Fisher, Waltham, 
MA, USA) was excited with a 545/547nm-tuned white light laser (WLL) and emission was collected from 555 
to 647 nm. Sequential acquisition was applied to avoid fluorescence overlap. A 660 nm conventional wisdom 
(CW)-depletion laser was used for both excitations. Images were acquired with a Leica HC PL APO 100×/1.40 oil 
STED White objective. CW-STED and gated-STED were applied to the fluorescent NPs and WGA, respectively. 
Collected images were de-convolved with Huygens Professional software (Scientific Volume Imaging, Hilversum, 
Netherlands) and analysed using Imaris 7.4.2 software (Bitplane, Belfast, UK).
Two-photon microscopy. Rat vena cava subjected to NPs-laden scaffolds has been fixed and stained with 
WGA, as previously described53, and imaged with the two-photon microscopy (Trim Scope II, LaVision BioTec, 
Bielefeld, Germany) which allow to imaging cell and NPs for the entire thickness with a 10–20 µm of Z-stack.
In-vitro HUVEC analysis. The sterile plastic material for the cell cultures was purchased from Costar, 
Corning (Amsterdam, The Netherlands), and PBS from Euroclone (Milano, Italy). The ATP colorimetric assay 
kit was obtained from Novus Biologicals (Centennial, CO, USA). MTT was provided by Sigma (St. Louis, MO, 
USA), which also supplied all of the other reagents unless otherwise specified.
Cell culture, treatment and proliferation/viability studies. HUVECs (purchased from Lonza, Basel, Switzerland) 
were grown in a fully supplemented EGM-2MV Bullet Kit (Lonza, Basel, Switzerland) at 37 °C in a 5% CO2 
humidified incubator, and used at passages 3–5 in the experiments. Before the treatments, cells were seeded in 
plates and cultured to 80–90% confluence.
Following, we seeded 3×105 of HUVECs in 2 ml of medium for 2–24–48 hrs before toxicology assays, apply-
ing the direct/indirect treatment previously used for the VSMCs.
The morphology of the cells was monitored using an inverted microscope (Olympus CK40-RFL, Tokyo, 
Japan) and their number was evaluated by cell counting in a Bürker hemocytometer.
Viability was also assessed by (3-(4,5-dimethyl-thiazol-2-yl)2,5-diphenyl tetrazolium bromide) MTT assay. 
The formazan crystals were solubilised, and the absorbance was measured using an automated microwell plate 
reader (Multiskan Ascent, Thermo Labsystems, Helsinki, Finland) at 550 nm.
Cellular ATP levels were determined using the ATP assay kit, following the manufacturer’s instructions.
All results were expressed as the percentage of controls (untreated cells).
The uptake of fluorescent NPs was evaluated by flow cytometry using a FC500 flow cytometer (Instrumentation 
Laboratory, Bedford, MA, USA). Data were processed using the FlowJo software package (Tree Star Inc., Ashland, 
OR, USA).
Statistics. Normal distribution of variables was checked by means of the Kolmogorov-Smirnov test. Statistics 
of variables included One sample T-test signed rank test, unpaired Student’s t-test, two-way ANOVA (post hoc 
analyses: Bonferroni test or Games-Howell test, when appropriate) Wilcoxon sign rank test and Kruskal-Wallis 
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(post hoc analyses: Dunn’s multiple comparison). Prism 6.0 software (GraphPad Software, San Diego, CA, USA) 
was used to assess the normality of the data and for statistical calculation. The details on the specific test used for 
each experiment are reported in the figure legends. Statistical significance was set at p < 0.05.
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